Frederick R. Appelbaum, Claudio Anasetti, Joseph H

Slides:

Advertisements

Similar presentations

Steven Joffe, Michelle M. Mello, E. Francis Cook, Stephanie J. Lee

Advertisements

Center for International Blood and Marrow Transplant Research Chronic Graft-versus- Host Disease Risk Score Predicts Mortality in an Independent Validation.

Clinical Evaluation of Oral Chronic Graft-Versus-Host Disease

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Mohamed A. Kharfan-Dabaja, Claudio Anasetti, Edgardo S. Santos

Easy-to-Read Informed Consent Forms for Hematopoietic Cell Transplantation Clinical Trials Ellen M. Denzen, Martha E. Burton Santibáñez, Heather Moore,

How to Treat MDS without Stem Cell Transplantation

Steven Joffe, Michelle M. Mello, E. Francis Cook, Stephanie J. Lee

Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia.

Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years Areej El-Jawahri, Shuli Li, Joseph.

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Bone Marrow Transplantation for Diamond-Blackfan Anemia

Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.

Generic Immunosuppressants in Hematopoietic Cell Transplantation

Anatomy of a Successful Practice-Changing Study: A Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker.

Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular.

Childhood Obesity and Outcomes after Bone Marrow Transplantation for Patients with Severe Aplastic Anemia Collin C. Barker, Manza-A. Agovi, Brent Logan,

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation Joseph Pidala, Claudio.

Impact of Ocular Chronic Graft-versus-Host Disease on Quality of Life

Recent Decrease in Acute Graft-versus-Host Disease in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants Stella M. Davies, Dan.

More Infections with Transplantation of Bone Marrow, Versus Peripheral-Blood Stem Cells, from Unrelated Donors Jo-Anne H. Young, MD, Brent R. Logan,

Jo-Anne H. Young, Brent R. Logan, Juan Wu, John R. Wingard, Daniel J

J. J. Nietfeld, Marcelo C. Pasquini, Brent R

Jennifer Crombie, Laura Spring, Shuli Li, Robert J. Soiffer, Joseph H

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma Peter Dreger, Ginna.

Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized.

Significant Improvement in Survival after Unrelated Donor Hematopoietic Cell Transplantation in the Recent Era Navneet S. Majhail, Pintip Chitphakdithai,

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation Vijaya.

Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive.

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

John R. Wingard, M. D. , Alan K. Leahigh, Dennis Confer, M. D

Dysglycemia Following Glucocorticoid Therapy for Acute Graft-versus-Host Disease Adversely Affects Transplantation Outcomes Joseph Pidala, Jongphil Kim,

Alternate-Day Micafungin Antifungal Prophylaxis in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Pharmacokinetic Study Parinda.

Cell-Based Therapy Using Umbilical Cord Blood for Novel Indications in Regenerative Therapy and Immune Modulation: An Updated Systematic Scoping Review.

Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase.

Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical.

Allogeneic Stem Cell Transplantation for Aplastic Anemia

NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Health-Related Quality of Life, Functional,

Trajectories of Quality of Life after Hematopoietic Cell Transplantation: Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network 0902.

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Exercise and Stress Management Training Prior to Hematopoietic Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

Guidance for Developing Phase II Cell Therapy Trial Proposals for Consideration by the Blood and Marrow Transplant Clinical Trials Network Edwin M. Horwitz,

Gerard Socié, K. Scott Baker, Smita Bhatia

Reduced Incidence of Acute and Chronic Graft-versus-Host Disease with the Addition of Thymoglobulin to a Targeted Busulfan/Cyclophosphamide Regimen H.

Richard Mitchell, John E. Wagner, Claudio Brunstein, Qing Cao, David H

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

John E. Levine, Sophie Paczesny, Stefanie Sarantopoulos

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality Margaret.

Blood and Marrow Transplant Handbook

Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow.

Mammen Chandy Biology of Blood and Marrow Transplantation

Treatment versus Transplant for Challenging Hematologic Disorders

Reduced-Intensity Conditioning for Unrelated Donor Progenitor Cell Transplantation: Long-Term Follow-Up of the First 285 Reported to the National Marrow.

Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation: Revised Definitions to Predict Survival Daniel Weisdorf,

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Infliximab for Managing Steroid-Refractory Acute Graft-versus-Host Disease Joseph Pidala, Jongphil Kim, Teresa Field, Ali McBride, Mohamed Kharfan-Dabaja,

Presentation transcript:

Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2014 Frederick R. Appelbaum, Claudio Anasetti, Joseph H. Antin, Harold Atkins, Stella Davies, Steven Devine, Sergio Giralt, Helen Heslop, Ginna Laport, Stephanie J. Lee, Brent Logan, Marcelo Pasquini, Michael Pulsipher, Edward Stadtmauer, John R. Wingard, Mary M. Horowitz Biology of Blood and Marrow Transplantation Volume 21, Issue 2, Pages 202-224 (February 2015) DOI: 10.1016/j.bbmt.2014.10.003 Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 The overall trial design depends on assignment to a high- or low-risk group based on GVHD grade and biomarkers. High-risk patients will be treated with prednisone, and new agents will be serially studied by addition to standard prednisone therapy. Low-risk patients will be randomized between a prednisone monotherapy or 1 of several single-agent nonsteroid alternatives. Biology of Blood and Marrow Transplantation 2015 21, 202-224DOI: (10.1016/j.bbmt.2014.10.003) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions